National Cancer Institute   Cancer Therapy Evaluation Program   Developing Cancer Therapies
CTEP HomeContactHelpSearch:

Pharmacogenetics Research Network/The Breast Cancer Intergroup/National Cancer Institute Summit
March 30-31, 2008
Agenda

A summit between the Pharmacogenomics Research Network (PGRN) and the Breast Cancer Intergroup (TBCI) of North America was held in Bethesda, Maryland on March 30 and 31, 2008. The goal of the meeting was to bring together experts in the fields of pharmacogenomics and breast cancer research in order to facilitate an exchange of ideas and understanding of potential collaborations. The following questions were addressed:

  1. What is the PGRN? How is the PGRN interacting with the Cooperative Groups? What are the lessons that can be learned from ongoing PGRN-Cooperative Group collaborations?
  2. What is TBCI?
  3. What are the scientific projects currently going on in PGRN?
  4. What technologies already exist in PGRN that might be applied to TBCI specimens/trials?
  5. What breast intergroup specimens are archived that might be available for immediate studies?
  6. What specimens should/could TBCI collect that would facilitate future studies?
  7. How can TBCI and NCI incentivize Cooperative Groups to initiate new collaborations with PGRN?

As a result of this meeting, it is clear that several of the Cooperative groups already have ongoing pharmacogenomic initiatives in breast cancer, as illustrated in the following table:

  1. CALGB: 40101
  2. ECOG: E2197
  3. NCIC: MA.17 and other new initiatives
  4. NCCTG: several new initiatives
  5. SWOG: S8897, S0221, and S0226

The meeting served to generate even more enthusiasm regarding the field, and introduced several investigators in both organizations as well as from NIH to one another. Consensus was reached on the following action items:

  1. TBCI will discuss instituting routine collection of white blood cells for germ line DNA on all patients entered into clinical trials.
  2. Intergroup trial consent forms will be revised and standardized to comply with National Institute of Health’s policy when available.
  3. Technology assessments are ongoing to determine the feasibility of using archived FFPE for germ line analysis of selected genes.
  4. Ongoing collaborations and initiatives will proceed, including RIKEN collaboration for GWAS
  5. PGRN and NCI will continue to discuss mechanisms to support collection, processing, and storage of germ line DNA as well as scientific projects to utilize these specimens.

Sunday, March 30, 2008 Evening
8:00-9:15 PM SESSION I: Welcome and Introduction Speaker
8:00-8:10 Welcome and Overview of Objectives and Agenda Dan Hayes
8:10-8:40 Overview of Pharmacogenomics Richard Weinshilboum
8:40-8:50 Overview of PGRN Rochelle Long
8:50-9:00 Overview of PGRN Cancer Working Group Howard McLeod
9:00-9:15 Overview of TBCI, CSC, and Specimen Resources Dan Hayes

Monday. March 31, 2008, Full Day
8:00-10:30 AM SESSION II: PGRN Accomplishments to Date in Cancer
8:00-8:25 Breast Cancer Pharmacogenomics/COBRA David Flockhart/COBRA
8.25-8.35 SNP analysis in FFPE tissue James Rae/COBRA
8:35-9:00 CYP2D6/Tamoxifen, Aromatase Inhibitors/May Additional Materials Matt Goetz & Jim Ingle/Mayo
9:00-9:30 Pharmacogenomic Advances in ALL/St. Judes Mary Relling/PAAR
9:30-10:00 Adult Solid Tumors Howard McLeod/CREATE
10:00-10:30 AM Break
10:30-12:00 AM SESSION III: Pharmacogenomics in Cooperative Group Breast Cancer-what�s happening now?
10.30-10.45 CALGB 40101 and others Deanna Kroetz
10.45-11.00 ECOG E2100 Bryan Schneider
11.00-11.15 NCIC CTG MA27/NCCTG initiatives Jim Ingle
11:15-11:30 NCIC other Geoffrey Liu
11.30-11.45 SWOG S8869 & SWOG S0221 Dan Hayes for Christine Ambrosone
11.45-12:00 SWOG S0226 Susan Nowell
12:00-1:00 PM Lunch
1:00-2:30 SESSION IV: Methods/Techniques/Infrastructure
1:00-1:15 Best Practices/Funding Sources, NCI program announcement Jo Anne Zujewski & Andy Freedman/NCI
1:15-2:30 PM SESSION V: Overview of Methods and Techniques
1:15-1:35 Association Studies in the Human Genome: Tatiana Foroud/COBRA
1:35-1:50 Whole Genome Analysis: techniques and pitfalls Todd Skaar/COBRA
1:50-2:10 Statistical and Bioinformatic Considerations Lang Li/COBRA
2:10-2:30 WGA: What it can do and what it can�t Jerry Rotter/PARC
2:30-3:30 PM SESSION VI: Discussion

Are there studies that can be done now using Archived Cooperative Group specimens?
Germ line (WBC) DNA
Immortalized Cell lines (germ line DNA and espression)
Somatic specimens (tumor)
Using individual Group Specimens (not Intergroup)

Additional Questions:
1) Should we institute routine prospective collection of specimens for future clinical trials within TBCI and within individual Cooperative Group studies?
2) Should all Intergroup protocols and consent form templates be changed?
3) Should we design prospective clinical trials using pharmacogenomics to guide therapy

Untitled Document

  Home   |   Contact   |   Privacy Notice   |   Accessibility National Cancer Institute   National Institutes of Health   Department of Health and Human Services   USA.gov